GBA1 and Parkinson disease: Finally, while the small molecules identified in this work may hold therapeutic potential for GBA1-PD, or even sporadic PD (3, 14, 15), our pipeline does not feature assays for quantitation of a PD phenotype, such as α-synuclein aggregation (50).